Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...

Elsewhere, Macquarie upgraded supermarket giant Woolworths, and Goldman Sachs downgraded drinks retailer Endeavour Group, ...

The International Finance Corporation (IFC), in partnership with the Swiss Secretariat for Economic Affairs (SECO), have launched the second phase of their supply chain finance (SCF) programme in ...

Arcfra is thrilled to introduce Arcfra Enterprise Cloud Platform v6.2, a release to provide unparalleled security and compliance for modern enterprises, especially in the rapidly evolving AI landscape ...

Information Services Corporation ("ISC" or the "Company") today reported on the Company's financial results for the fourth quarter and year ended December 31, 2024. Commenting on ISC's results, Shawn ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...

Melbourne-based biotech Telix Pharmaceuticals has announced that its prostate cancer diagnostic agent Illuccix has been ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...

Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.

A weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The trades have all taken place ...

TLX opened at $17.30 on Friday. The firm’s fifty day simple moving average is $17.47. Telix Pharmaceuticals Limited American Depositary Shares has a 52-week low of $14.01 and a 52-week high of $30.36.